Nalaganje...

Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance

The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Target Oncol
Main Authors: Lorusso, Domenica, García-Donas, Jesús, Sehouli, Jalid, Joly, Florence
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2020
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7283207/
https://ncbi.nlm.nih.gov/pubmed/32495160
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-020-00715-z
Oznake: Označite
Brez oznak, prvi označite!